Food and Drug Administration
Arthritis Advisory Committee
July 29, 2002
Slides
Pain, Dr. James Witter, MDD PhD, FDA htm ppt
1992 Analgesic Guidance and Current Issues, Dr. Christina Fang, MD, FDA htm ppt
Comments on: The Guideline for the Clinical Evaluation of Analgesic Drugs, Dr. Sharon Hertz, MD, FDA htm ppt
Pain-Basic Science Implications for Analgesia and Analgesics, Clifford Woolf, Mass. General Hospital & Harvard Medical School htm ppt
Chronic Pain, Dr. Lee Simon, MD, FDA htm ppt
Back Pain - Chronic Issues, Dr. David Borenstein, MD, George Washington U. Medical Ctr. htm ppt
Pain, Dr. James Witter, MD PhD, FDA htm ppt
Opioid Toxicity, Dr. Nathaniel Katz, MD, Harvard Medical School htm ppt
Time-Specific Measurements vs. Time-Weighted Average for Pain in Chronic and Acute Analgesia Trials, Dr. Laura Lu, PhD, FDA htm ppt
Open Public Hearing
Analgesic Drug Development for Chronic Pain, Dr. Najib Babul, PharmD., TheraQuest Biosciences htm ppt
Development of New Guidelines for Analgesics/Drugs Intended for the Treatment of Pain, Dr. Kenneth Verburg, PhD htm ppt
How to Demonstrate Efficacy of Regimen in Chronic Pain at Week W, Dr. Eugene Laska, PhD, NY htm ppt
Make Analgesic Approval Trials More Useful to Clinicians, Dr. Daniel Carr, MD Tufts-New England Medical Ctr. htm ppt
Nosology of Chronic Pain, Methodology of Efficacy Trials, and Long-term Safety, Dr. Thomas Schnitzer, MD, PhD, Northwestern U. Feinberg School of Medicine htm ppt